Laura Pala

4.1k total citations · 2 hit papers
66 papers, 2.1k citations indexed

About

Laura Pala is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Laura Pala has authored 66 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Laura Pala's work include Cancer Immunotherapy and Biomarkers (21 papers), Myasthenia Gravis and Thymoma (9 papers) and Melanoma and MAPK Pathways (8 papers). Laura Pala is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Myasthenia Gravis and Thymoma (9 papers) and Melanoma and MAPK Pathways (8 papers). Laura Pala collaborates with scholars based in Italy, United States and Spain. Laura Pala's co-authors include Fabio Conforti, Tommaso De Pas, Vincenzo Bagnardi, Giuseppe Viale, Richard D. Gelber, Aron Goldhirsch, Emilia Cocorocchio, Pier Francesco Ferrucci, Carlo Maria Rotella and Chiara Lazzeri and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Cell.

In The Last Decade

Laura Pala

63 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

2018 666 citations Fabio Conforti, Laura Pala et al. profile →
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma

2021 192 citations Pier Francesco Ferrucci, Laura Pala et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura Pala Italy	18	1.3k	525	523	348	270	66	2.1k
Dennis Cooper United States	27	1.1k 0.8×	466 0.9×	367 0.7×	461 1.3×	459 1.7×	112	2.8k
Ye Guo China	28	1.0k 0.8×	264 0.5×	393 0.8×	684 2.0×	279 1.0×	217	2.3k
Katherine C. Fuh United States	25	669 0.5×	487 0.9×	297 0.6×	537 1.5×	377 1.4×	114	2.0k
Jacques‐Olivier Bay France	25	721 0.5×	391 0.7×	538 1.0×	702 2.0×	121 0.4×	151	2.4k
Cinzia Solinas Italy	28	1.7k 1.3×	1.0k 1.9×	445 0.9×	421 1.2×	131 0.5×	80	2.4k
Ulf Petrausch Switzerland	23	1.1k 0.8×	450 0.9×	289 0.6×	289 0.8×	231 0.9×	62	1.6k
Julio Delgado Spain	35	1.0k 0.8×	939 1.8×	228 0.4×	647 1.9×	112 0.4×	195	3.6k
Masoud Azodi United States	32	1.4k 1.0×	353 0.7×	396 0.8×	809 2.3×	531 2.0×	162	3.3k
Ruth Vera Spain	24	1.3k 1.0×	347 0.7×	394 0.8×	252 0.7×	357 1.3×	102	1.8k
Theodoros P. Vassilakopoulos Greece	26	1.6k 1.2×	733 1.4×	316 0.6×	540 1.6×	162 0.6×	167	3.1k

Countries citing papers authored by Laura Pala

Since Specialization

Citations

This map shows the geographic impact of Laura Pala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Pala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Pala more than expected).

Fields of papers citing papers by Laura Pala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Pala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Pala. The network helps show where Laura Pala may publish in the future.

Co-authorship network of co-authors of Laura Pala

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Pala. A scholar is included among the top collaborators of Laura Pala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Pala. Laura Pala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Conforti, Fabio, Laura Pala, Tommaso De Pas, et al.. (2025). Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence. Journal of Clinical Oncology. 43(30). 3237–3244.

Pala, Laura, Eleonora Pagan, Tommaso De Pas, et al.. (2024). “Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.”. The Breast. 73. 103672–103672. 1 indexed citations

Pala, Laura, Eleonora Pagan, Chiara Oriecuia, et al.. (2024). Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis. EClinicalMedicine. 73. 102681–102681. 5 indexed citations

Pagan, Eleonora, Laura Pala, Chiara Oriecuia, et al.. (2024). Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis. Frontiers in Immunology. 15. 1340979–1340979. 2 indexed citations

Pala, Laura, Tommaso De Pas, Eleonora Pagan, et al.. (2023). Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials. The Breast. 69. 258–264. 1 indexed citations

Conforti, Fabio, Laura Pala, Tommaso De Pas, et al.. (2023). Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research. Clinical Cancer Research. 30(6). 1093–1103. 1 indexed citations

Pas, Tommaso De, Giovanna Rossi, Paola Bossi, et al.. (2023). Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review. Current Oncology. 30(3). 3494–3499. 4 indexed citations

Conforti, Fabio, Laura Pala, Chiara Corti, et al.. (2023). High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study. Lung Cancer. 176. 98–102. 1 indexed citations

Pala, Laura, Tommaso De Pas, Chiara Catania, et al.. (2023). Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis. Seminars in Oncology. 50(6). 140–143. 1 indexed citations

10.

Pala, Laura, Tommaso De Pas, Chiara Catania, et al.. (2022). Sex and cancer immunotherapy: Current understanding and challenges. Cancer Cell. 40(7). 695–700. 35 indexed citations

11.

Pala, Laura, Vincenzo Bagnardi, Francesca Tettamanzi, et al.. (2022). Genetic Alterations of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis. Molecular Diagnosis & Therapy. 27(1). 5–13. 1 indexed citations

12.

Pala, Laura, Fabio Conforti, Eleonora Pagan, et al.. (2021). Different Response to Immunotherapy According to Melanoma Histologic Subtype. Journal of Immunotherapy. 45(2). 119–124. 6 indexed citations

13.

Repetto, Matteo, Fabio Conforti, Mariarosaria Calvello, et al.. (2021). Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy. European Journal of Cancer. 153. 162–167. 9 indexed citations

14.

Saponara, Maristella, Laura Pala, Fabio Conforti, et al.. (2020). Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. Therapeutic Advances in Medical Oncology. 12. 3863592042–3863592042. 4 indexed citations

15.

Pala, Laura, Fabio Conforti, Maristella Saponara, et al.. (2020). Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19. Seminars in Oncology. 47(5). 302–304. 12 indexed citations

16.

Cocorocchio, Emilia, Chiara Martinoli, Sara Gandini, et al.. (2020). Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors. Clinical & Translational Oncology. 22(10). 1818–1824. 7 indexed citations

17.

Conforti, Fabio, Paolo Tarantino, Pamela Trillo Aliaga, et al.. (2020). Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. Cancer Treatment Reviews. 92. 102133–102133. 5 indexed citations

18.

Conforti, Fabio, Laura Pala, Vincenzo Bagnardi, et al.. (2019). Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. JNCI Journal of the National Cancer Institute. 111(8). 772–781. 173 indexed citations

19.

Conforti, Fabio, Laura Pala, Eleonora Pagan, et al.. (2019). Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence. Breast Cancer Research. 21(1). 153–153. 13 indexed citations

20.

Conforti, Fabio, Laura Pala, Vincenzo Bagnardi, et al.. (2018). Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y.C. Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients’ Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737–46. European Urology. 75(2). e34–e35. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact